This work reports the tumoricidal effects of a novel investigational humanized anti-CD19 monoclonal antibody ). An a-fucosylated antibody with increased affinity for human FcgRIIIA, Medi-551 is shown to mediate both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Medi-551/CD19 complexes internalize slowly (45 h) and thus remain accessible to effector cells for prolonged periods. We evaluated in vitro ADCC and ADCP activities of primary human natural killer (NK) cells and macrophages against precursor-B (pre-B) acute lymphoblastic leukemia (ALL) cell lines and pediatric patient blasts. Fluorescent imaging studies document immunological synapses formed between anti-CD19-bound target leukemia cells and effector cells and capture the kinetics of both NK-mediated killing and macrophage phagocytosis. Genetic polymorphisms in FcgRIIIA-158F/V modulate in vitro activities of effector cells, with FcgRIIIA-158V homozygotes or heterozygotes showing the strongest activity. Medi-551 treatment of severe combined immunodeficiency (SCID) mice engrafted with human pre-B cells led to prolonged animal survival and markedly reduced disease burden in blood, liver and bone marrow. These data show that anti-CD19 antibodies effectively recruit immune cells to pre-B ALL cells and support a move forward to early phase trials in this disease.
INTRODUCTION
Precursor-B (pre-B) acute lymphoblastic leukemia (ALL) is the most common malignancy in children and young adults. Although cure rates approach 80%, 1 survivors may develop one or more therapyrelated toxicities after receiving dose-intensified treatment. Leukemic relapse occurs in B20% of patients 2 and for this subset novel treatments are critically sought. There is a clear need for less toxic, targeted therapies capable of engaging the immune system as opposed to causing its compromise. 1 Immunotherapy using antibodies to leukemia cell surface antigens has potential for extending the spectrum of treatment options to most patients with pre-B ALL. Monoclonal antibodies involve various mechanisms to target cancer cells, including natural killer (NK)-mediated killing via FcgRIIIA (CD16) and phagocytosis by macrophages through their repertoire of Fcg receptors (FcgRI, FcgRIIA, FcgRIII). [3] [4] [5] [6] [7] [8] Antibody-based therapies can also involve complement-dependent cytotoxicity or directly modify the activity or ligand capabilities of cell surface receptors on target cells. 3, 9 In B-cell diseases, the anti-CD20 monoclonal antibody rituximab has improved outcome in B-cell lymphomas. [10] [11] [12] However, CD20 surface expression is typically low or absent during early stages of B-cell development and has poor response in ALL. 13 CD19 is a B lymphocyte-specific surface antigen expressed by early pre-B cells from the time of heavy chain rearrangement, 14 and it can serve as a coreceptor for the B cell receptor (BCR). 15, 16 Because CD19 is typically detected on neoplasms of B-cell origin, including many B-cell derived leukemias and lymphomas, it is an attractive target for antibody-mediated therapy. Several CD19 specific antibodies, including unconjugated and bispecific reagents such as anti-CD19/CD3 or anti-CD19/CD16, are under development, thus far for the treatment of B-cell-mediated diseases. [17] [18] [19] [20] [21] Medi-551 is an affinity-optimized, humanized anti-CD19 investigational monoclonal antibody produced in eucaryotic cells that lack a1,6-fucosyltranserase. 22 As a consequence, the antibody's N-linked carbohydrates lack fucosylation and exhibit approximately nine-fold increased affinity to human FcgRIIIA and mouse FcgRIV. 23 Prior work has shown Medi-551 effectively binds several classes of B-lineage neoplastic cells, including primary chronic lymphocytic leukemia and ALL blasts from adult patients and is devoid of complement-dependent cytotoxicity activity. 24 Medi-551 inhibited tumor growth in a SCID mouse xenograft model of human B-cell lymphoma and stimulated NK-mediated killing of adult leukemia cells in vitro. The combination of Medi-551 with rituximab resulted in prolonged suppression of tumor growth (B60 days). 24 In vivo studies in human CD19/CD20 transgenic mice support continued development of Medi-551 for autoimmune disease and primarily implicated macrophages in the clearance of B cells in mice. 22 Here we report preclinical studies of Medi-551 using as targets both pre-B ALL cell lines and blasts from pediatric patients and primary human effector cells. We found significant variability in the killing capacity of NK cells from different human donors, linked to genetic polymorphisms in FcgRIIIA-158 that affect binding to a-fucosylated immunoglobulin G (IgG). 25, 26 Human macrophages express additional activating Fcg receptors (FcgRI and FcgRIIA), 5, 27 rendering them less dependent on high-affinity FcgRIIIA binding for phagocytosis of opsonized leukemia cells. Importantly, treatment of SCID mice engrafted with pre-B ALL cells led to significant reduction in tumor burden and prolonged mice survival with no observable complications. Taken together, results suggest that further development of Medi-551 is warranted in support of early phase trials in relapsed, pediatric pre-B malignancies.
MATERIALS AND METHODS Antibodies
Medi-551 was produced at MedImmune, Gaithersburg, MD, USA according to good manufacturing practices, using a fucosyltransferase-deficient producer CHO cell line (BioWa Potelligent Technology, BioWa Inc., Princeton, NJ, USA). A-fucosylated R347 IgG1 (R347aFuc) served as a negative isotype-matched control. Antibody labeling kits (Invitrogen, Carlsbad, CA, USA) were used for Alexa dye conjugation. Mouse antihuman CD137, CD16, CD32, CD64 were from Abcam (Cambridge, MA, USA). Mouse anti-human granzyme, perforin and CD107a were from BioLegends (San Diego, CA, USA). Secondary antibodies were Alexa Fluor-488F(ab)'2 of anti-mouse IgG (Invitrogen) or DyLight488 Affini Pure F(ab)'2 of anti-rabbit IgG (Jackson Laboratories, West Grove, PA, USA).
Cells and reagents
Pre-B ALL cell lines (697, MHH-Call3, Nalm6, RS4;11) were cultured in RPMI-1640 medium, 10% fetal bovine serum (FBS; 20% for MHH-Call3), 50 U/ml penicillin-streptomycin (Pen-Strep), 2 mM L-glutamine. Peripheral blood mononuclear cells were isolated from buffy coats of normal donors (United Blood Services, Albuquerque, NM, USA) by centrifugation in a Ficoll-Paque (GE Healthcare, Piscataway, NJ, USA) density gradient. Primary NK cells and monocytes were negatively isolated using Dynabeads Untouched Human NK Cells or Monocytes (Invitrogen). NK cells were cultured in Iscove's modified Dulbecco's medium (IMDM), 20% FBS, 10% AB-human serum (3H Biomedical), 50 U/ml pen-strep, 2 mM L-glutamine, 1 Â non-essential amino acids, 1 mM sodium pyruvate, 50 mM b-mercaptoethanol (Sigma, St. Louis, MO, USA) and stimulated with interleukin-2 (IL-2, 100 U/ml; Peprotech, Rocky Hill, NJ, USA). Macrophages were differentiated from monocytes by culturing 7 days in RPMI-1640, 10% FBS, pen-strep, L-glutamine, recombinant human macrophage colony stimulating factor (250 ng/ml; Peprotech). Bone marrow samples were acquired at diagnosis from pediatric patients with written, informed consent (HRPO-05-435). Leukemia blasts were enriched by Ficoll-Paque centrifugation. 28 Quantitation of cell surface expression CD19 receptors were enumerated by flow cytometry using anti-hCD19 FITC antibody (BD Pharmingen, Sparks, MD, USA) and Quantum Simply Cellular anti-Mouse IgG beads by manufacturer's protocol (Bangs Laboratories, Fishers, IN, USA). Bead populations were labeled to saturation with antihCD19 FITC antibody, providing a calibration curve for staining of pre-B ALL cells. The number of CD19 on cell surface was calculated from regression curve, associating fluorescence channel value to the antibody-binding capacity of beads.
Genetic analysis
Polymorphism of FcgRIII-158 F/V was determined by nested PCR-based allele-specific restriction assay. 10, 29 Acid stripping internalization assay Pre-B ALL cells and patient blasts (0.5 Â 10 6 /ml) were incubated in duplicate with 1 mg of Medi-551
Alexa488 or R347aFuc Alexa488 for specified times. One sample per set was resuspended in 2% paraformaldehyde (PFA; Electron Microscopy Sciences, Fort Washington, PA, USA) for 15 min fixation. Other samples were incubated for 3 min in stripping buffer (1 mM NaCl, 0.2 M glacial acetic acid, pH 2.7) to remove non-internalized antibody, followed by fixation in 2% PFA. Samples were analyzed on a BD-FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). Murine xenograft model of pre-B ALL With local institutional approval (ARF-100510), female SCID mice (10-12 week-old; National Cancer Institute, Rockville, MD, USA) were housed in a specific pathogen-free, AAALAC accredited facility as described. 28 Mice were engrafted with 5 Â 10 6 697 cells by tail vein injection on day zero. After five days, mice were divided into groups that received a regimen of Medi-551 injections (3 mg/kg), the same dose of control antibodies (R347aFuc) or normal saline alone. These treatments were administered twice weekly for total of five doses. To assess tumor burden, groups of 6-7 mice for each condition were killed at 21 days post-engraftment. Disease burden was assessed in blood smears and slides prepared from formalin-fixed, paraffin-embedded liver and bone marrow utilizing Wright and hematoxylin and eosin stains, and immunohistochemistry-based detection of human hCD10. 28 To evaluate survival, groups of 10 mice were treated with Medi-551, R347aFuc and saline control. Criteria for humane sacrifice were significant weight loss up to 15%, reduced activity and moribund condition.
RESULTS
Medi-551/CD19 complexes persist on the cell surface for prolonged periods The rate of internalization of antigen-antibody complexes can be a key factor in effectiveness of therapeutic antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), as only antibodies bound to the cell surface are accessible to effector cells. Supplementary Table 1 reports the characteristics of experimental cell lines that represent several common pre-B ALL genotypes. Three of the cell lines (Nalm6, 697, MHH-Call3) have a similar range of CD19 surface expression (4170 000/cell). Only RS4;11 cells express low levels of CD19 (B4500/cell). Table 1 reports characteristics including National Cancer Institute risk assessment, genetic abnormalities and phenotypic markers of leukemia cells. CD19 expression levels in this group ranged from a low of B60 000 to a high of B145 000.
FcgRIIIA-158 F/V polymorphism affects Medi-551 ADCC activity against pre-B ALL cell lines and patient-derived blasts A-fucosylated Medi-551 was shown to have no direct effect on viability or proliferation of all pre-B ALL cell lines, as compared with both untreated and isotype-matched controls ( Supplementary Figures 2A and B) . Similarly, no direct killing was observed for patient blasts incubated for up to 24 h with Medi-551 (Supplementary Figures 2C and D) . As CD19 has been linked to PI3-kinase activation, 30 we also tested whether crosslinking with Medi-551 altered levels of AKT/protein kinase B phosphorylation downstream of PI3K (Supplementary Figure 2E) . We observed no change, indicating that in the absence of effector cells Medi-551 does not induce detectable changes in CD19-mediated signaling.
Next, Medi-551 was tested for its ability to promote NKmediated killing of pre-B ALL cells. Figure 2a reports results of LDH assays for target cell cytotoxicity. IL-2-stimulated NK cells from eight healthy donors were incubated with 697 cells opsonized with Medi-551. Two conclusions were drawn: first, optimal killing was achieved at doses ranging from 0.1-10 mg/ml Medi-551; second, when incubated under the same conditions, the killing response of NK cells from different healthy donors varied considerably. Although NK cells from several donors killed 60%-80% of target cells, three of eight NK preparations exhibited relatively poor killing capability (o20%).
We speculated that the variability in NK-mediated killing efficiency might be linked to genetic polymorphisms in the gene encoding FcgRIIIA receptor, based upon reports that allotypes with V/V, F/V or F/F at amino acid position 158 differ in IgGbinding affinity and immune cell effector function.
11,20 A PCR-based assay was implemented to determine the status of FcgRIII-158 polymorphisms for each NK donor. Of the pool of 23 donors, 11 individuals were determined to be heterozygous at this position (FcgRIIIA-158F/V). Nine individuals were homozygous for the weak binding 158F/F allotype and only two individuals were homozygous for the strong binding 158V/V allotype.
We evaluated the in vitro killing efficiency of NK cells from this donor pool, using four pre-B ALL cell lines as target cells (Figures  2b-d) . Results clearly link NK-mediated killing of leukemia cells with FcgRIIIA allelic variation, with the trend of 158V/V4F/V4F/F. Figure 2b shows representative results using NK cells from donors homozygous for FcgRIIIA-158F/F, which proved capable of killing up to 30% of 697, Nalm6 or MHH-Call3 cells during the 4 h incubation period. However, NK cells from 158F/F donors were ineffective at killing RS4;11 cells that have low CD19 levels. NK cells from donors homozygous for FcgRIIIA-158V/V were most effective, reaching 40%-80% in vitro killing of 697, Nalm6 and MHH-Call3 cells and up to 33% of killing of RS4;11 cells despite low numbers of CD19 surface expression. NK cells from heterozygous donors were also effective in the in vitro cytotoxicity assay, indicated that the expression of at least one FcgRIIIA-158V form ensures highly effective ADCC activity.
NK-mediated cytotoxicity results were next confirmed using primary cells isolated from bone marrow of pediatric patients with pre-B ALL. Figures 2e-g show that the killing efficiency of NK cells against patient blasts bound to Medi-551 followed similar trends to that of the pre-B ALL cell lines, where efficient ADCC activity is linked to FcgRIIIA-158V/V and FcgRIIIA-158F/V polymorphisms, but not with the FcgRIIIA-158/F/F variant. We note that CD19 expression was not a limiting factor on this group of patients, since 50% killing was observed even for blasts having B60 000 CD19 molecules/cell (patient #045-11) ( Figure 2f ). As expected, incubation of pre-B ALL cell lines and 
Macrophage and NK-mediated killing of pre-B ALL K Matlawska-Wasowska et al Figure 3c ) and typically results in a dramatic swelling of the target cell membrane that precedes cell lysis and cell death as reported before. 31, 32 Notably, we observed that NK cells from FcgRIIIA-158F/F donors were capable of forming synapses despite their lower killing efficiency (Supplementary Figure 4) , suggesting that the lower affinity interaction can support binding but is less efficient at initiating FcgRIII-mediated degranulation.
Figures 3d-f illustrate the steps in the NK-mediated killing process. Initially, NK lytic granules are well distributed (granzyme label, Figure 3d ), followed by migration to the synapse (perforin label, Figure 3e ). Subsequently, fusion of the lytic granules results in release of perforin into the synaptic cleft and uptake of granzyme into the cytosol of the target cell (Figure 3f) , where red endocytic vesicles identify the CD19 þ leukemia cell. Alexa594 and green fluorescent label for CD16 occurs only at the synapse between the two cells (yellow region in Figure 3g ).
Prior studies have demonstrated that activated NK cells upregulate a unique profile of cell surface antigens, including CD107a and CD137. 33, 34 Micrographs in Figures 3h-i show that the interaction between NK and target cells has a reciprocal effect that activates NK cells, as indicated by the marked membrane labeling of CD107a and CD137.
Medi-551 induces potent in vitro ADCP activity against pre-B ALL cell lines and patient blasts We developed an assay for phagocytosis of antibody-coated leukemia target cells by human monocyte-derived macrophages (MF), based upon microscopic analysis. This assay is illustrated in Figure 4f ) and FcgRII (CD32; Figure 4g ) in addition to FcgRIIIA (CD16; Figure 4h ).
Having confirmed that the macrophage effector cells expressed multiple Fcg receptors in these experiments, we next sought to determine the relative importance of FcgRIIIA-158 polymorphisms in the phagocytosis process ( Figure 5) . Results document the relative phagocytic activity for macrophages derived from donors with all three FcgRIIIA-158 (F/F, F/V, V/V) allotypes, using our panel of pre-B ALL cell lines (Figures 5a-c) or patient blasts (Figures 5d-f) as targets. Robust phagocytic activity (80%-100%) was observed when the combination included: (1) Alexa488 (1 mg/ml; 1 h) and nucleoli of these cells were stained with Hoechst 33342. Next, 697 cells were coincubated with MF from a FcgRIIIA-158F/V donor at T:E ratio 1:3 for indicated intervals. Cells were fixed with 2% PFA and analyzed by confocal microscopy. Images in c-e represent data from live cell imaging, performed in RPMI-1640 phenol free medium, 2% FBS. Target cells were preincubated with green fluorescent antibody (1 mg/ml Medi-551
Alexa488 for 1 h) and MF were stained with Orange Cell Mask. Target and effector cells (FcgRIIIA-158F/V) were coincubated at a T:E ratio of 1:3 for up to 30 min while imaging. Macrophages were seen to form 'synapse-like' structures with antibody-bound pre-B ALL (c) cells and patient blasts (d, e). Images in f-h report results of immunofluorescence labeling for Fcg receptors on the surface of MF in contact with target cells. For these surface antigens, samples were chilled and labeled with antibodies followed by PFA fixation. The presence of FcgRIIIA (h, CD16), FcgRIIA (g, CD32) and FcgRI (f, CD64) suggest the involvement of these receptors in ADCP of target cells. Secondary antibodies used here were either anti-mouse IgG Alexa Fluor 488 or DyLight488 Affini Pure F(ab)'2 fragments. one high-affinity allele of FcgRIIIA-158V and (2) target cells with CD19 expression in the range of 60 000-185 000 (Tables 1 and 2 ). It is remarkable that significant phagocytosis was observed for RS4;11 target cells, with only B4500 cell surface CD19 receptors, provided the macrophages were either homozygous or heterozygous for FcgRIIIA-158F. Macrophages from donors homozygous for FcgRIIIA-158F/F were capable of taking up 697, Nalm6 and MLL-Call3 pre-B ALL cells, as well all patient blast samples, with efficiencies of up to 40%. We conclude that maximal phagocytosis occurs when effector cells expressing FcgRIIIA-158V are presented with leukemia target cells, bearing abundant Medi-551-CD19 complexes (X60 000 CD19 molecules for this patient group). Nevertheless, the presence of additional activating forms of FcgR (FcgRIIA/CD32 and FcgRI/CD64) on macrophages can mediate significant phagocytosis of leukemia target cells. Isotype-matched R347aFuc control antibodies did not mediate phagocytosis of pre-B ALL and patient blasts (Supplementary Figure 6) .
Medi-551 has anti-tumor activity in murine xenograft model of human pre-B ALL Our final goal was to evaluate the anti-tumor ability of Medi-551 in an in vivo model, using SCID mice engrafted with human 697 pre-B ALL cells ( Figure 6 , Table 2 ). Although NK cells in these mice lack FcgRIV (orthologous of human FcgRIII) their macrophages are expected to be fully functional against Medi-551-opsonized cells. Post-euthanasia necropsies of liver and bone marrow from mice killed at 21 days post-engraftment revealed the significant decrease (Po0.0005; Fisher's exact test) of leukemia burden in experimental group, as compared with both the control groups that had profound histological evidence of disease progression ( Figure 6a , Table 2 ). The anti-tumor efficacy of Medi-551 was further investigated by assessing endpoint survival. As shown in the Kaplan-Meier plot in Figure 6b , Medi-551 treatment prolonged survival in engrafted SCID mice when compared with PBS-vehicle and R347aFuc controls (log rank, Po0.005).
DISCUSSION
The targeted recruitment of immune effector cells, particularly macrophages and NK cells, is important for therapeutic efficacy of monoclonal antibodies. Critical factors include the binding affinity and stability of the complex formed between mAb-coated target cells and Fcg receptors on effector cells, as stable direct contacts are required for both ADCC-and ADCP-mediated killing of cancer cells. 35, 36 Therefore, current research in the field has focused on engineering the Fc fragment of monoclonal antibodies (mAbs) to improve binding to effector cells. 9, 25, 26, 35, 37 Here, we describe the first preclinical data for investigational Medi-551 therapeutic antibody in a pediatric setting. We provide evidence that Medi-551: (1) induces ADCC of pediatric pre-B ALL cells in vitro, with the highest efficiency linked to an NK genotype of FcgRIIIA-158V/V or 158F/V; (2) mediates potent ADCP activity against pre-B ALL cells in vitro, with the caveat that maximal phagocytic activity depends on both the expression of FcgRIIIA-158V and high levels of antigen and (3) lowers leukemia burden to prolong survival in pre-B ALL xenograft model. Previous studies have linked the clinical efficacy of anti-CD20 rituximab antibodies to patients with FcgRIII-158V/V genotype. 10, 38 Genetic variations at this locus apparently do not distribute with expected Mendelian frequencies, as we and others 10, 38 find that only 10%-15% of the human population are homozygous for the high-affinity FcgRIIIA-158V/V. Glycoengineered mAbs represent one strategy to make immunotherapy accessible to a wider group of patients, as even the weaker FcgRIIIA-158F allotype has improved binding to a-fucosylated IgG. 10, 38 The concept that Fc engineering can enhance immune effector function of mAbs is supported by data with other mAbs such as anti-CD19 (XmAb5574, MDX-1342), 17, 18, 39, 40 anti-CD20, 41 anti-CD40 (XmAbCD40) 37 and anti-CD70. 9 Live cell imaging of antibody-dependent killing of leukemia cells by NK cells and macrophages is a novel aspect of our study. We demonstrate that Medi-551/CD19 complexes are initially uniformly distributed on the leukemia cell surface and remain available to effector cells for many hours in vitro. The slow endocytic rates are consistent with prior reports. 42, 43 Remarkably, tight binding to effector cells is associated with redistribution of Medi-551/CD19 complexes to synapses between the engaged cells. In the context of NK cells, the synapse architecture has been proposed to critically control the polarized secretion of cytotoxic proteins, selectively killing target cells and protecting bystander cells. 44, 45 We found that NK cells from all donors, regardless of FcgRIIIA polymorphism status, could form synapses with antibodybound target cells. However, efficient killing was strongly associated with expression of FcgRIIIA-158V on the NK cell. This suggests that FcgRIIIA receptors accumulating at the synapse must remain stably bound to IgG-Fc on the target cell in order to efficiently signal to polarized degranulation. Once productively engaged, NK cell activation leads to upregulation of the cell surface markers CD107a and CD137. This observation may be useful way to monitor mobilization of NK cells in patients treated with therapeutic antibodies that rely on the ADCC pathway. Our data agree with Ward et al. 24 , who concluded that the number of CD19 receptors present on the surface of B cells is important for ADCC. Although these observations are likely to be relevant to other anti-CD19 antibodies, we note that ADCC activity may be influenced by higher rates of CD19 internalization under specific conditions, as suggested by studies of chronic lymphocytic leukemia cells treated with XmAb5574. 18 Our microscopy studies also shed light on factors that regulate phagocytosis of Medi-551-opsonized leukemia cells. Microscopic analysis provided an accurate method to quantitate phagocytosis by primary human and mouse monocyte-derived macrophages, showing that individual cells could engulf multiple target cells over a matter of hours. Using this assay, we demonstrated that blasts from children-bound sufficient anti-CD19 antibodies to induce highly efficient macrophage activity. Although the highest efficiency for ADCP was seen for macrophages with the FcgRIIIA-158V/V or 158F/V genotypes, significant internalization of patient samples was also observed for macrophages expressing FcgRIIIA-158F/F. The poor uptake of the RS4;11 cells, with very low CD19 expression, suggests that the quantitation of antigen levels on patient blasts may be the most important criteria for stratifying those patients who are more likely to respond to anti-CD19 immunotherapy.
Effector functions of macrophages relay on interplay between all Fcg receptors, including the activating forms of FcgRI, FcgRIIA and FcgRIII as well as the inhibitory receptor, FcgRIIB present on the cell surface. 5, 6, 8, 27 Richards et al. 6 showed that human macrophages express high levels of FcgRIIA and FcgRIIB, lower but significant levels of FcgRIIIA and low levels of FcgRI. Based upon incomplete reliance on high-affinity FcgRIIIA expression for phagocytosis of Medi-551-bound leukemia cells ( Figure 5 ), we expect that the other FcgR receptors detected by immunolabeling are active participants (Figures 4g-i) . In particular, FcgRIIA is known to mediate phagocytosis of antibody-bound target cells. 5, 6, 46 Another anti-CD19 antibody, XmAb5574, was engineered by introducing two point mutations in the Fc fragment for increased affinity to activating FcgRIIIA, FcgRIIA and FcgRI, but was also found to bind inhibitory FcgRIIB; it has been shown to mediate ADCC and ADCP against NHL (non-Hodgkin's lymphoma) and chronic lymphocytic leukemia. 17, 18 Like Medi-551, MDX-1342 is an example of an antibody specifically engineered for increased affinity to FcgRIIIA, and shows enhanced ADCP and ADCC activity against human lymphoma cells. 40 However, clinical development of MDX-1342 has been discontinued. Thus, it is reasonable to conclude that a-fucosylated anti-CD19 antibodies elicit particularly strong phagocytic activity from FcgRIIIA-bearing macrophages, but also evoke participation of other Fcg receptors. Medi-551 was generated by humanization and affinity maturation, which improved the kinetics of binding associated with decreased internalization rate and prolonged persistence on the target cell surface, further improving in vitro potency relative to the parental antibody (Herbst, unpublished) . By comparison, other anti-CD19 targeted therapies (SAF3419, BiTE) differ considerably in their mechanism of action by relying on either toxin delivery or T-cell engagement to kill target cells. 47, 48 Mouse xenograft models are most informative for macrophagemediated responses to humanized antibodies, as murine NK cells lack FcgRIV, the ortholog of human FcgRIIIA. Our study in SCID mice, engrafted with human 697 pre-B ALL cells, also shows that macrophages alone can reduce leukemic progression. We confirmed that only five doses of therapeutic antibody significantly lowered leukemia burden and extended mouse survival, if administered within 5 days of engraftment before complete bone marrow involvement. Therapeutic effect was seen at a dose of 3 mg/kg, previously established as an optimal dose for depletion of endogenous and human B cells in mice. 22, 24 Others have pointed out that the different types and distribution of Fcg receptors in mice vs human can cause difficulties in extrapolating in vivo results from mice to potential clinical application in humans. 25, 37 Nevertheless, strong in vitro ADCC activity makes a compelling case that NK cell recruitment may enhance therapeutic activity in patients.
The strong potential of Medi-551 as an anti-leukemia and lymphoma agent merits further development to support moving this mAb into early phase trials in relapsed pre-B ALL, where CD19 
Abbreviations: ALL, acute lymphoblastic leukemia; pre-B, precursor-B. Po0.0005. À 0 nodules. þ 1-10 nodules. þ þ 11-30 nodules. þ þ þ 430 nodules, large areas infiltrated.
expression is typically maintained at high levels. 49 Based on the results of this study, we predict clinical responses when administered as post-induction therapy, after the initial reduction in tumor burden and followed by post-remission recovery effector cells. Consideration should be given to combination with other mAbs, chemotherapeutic drugs or immunomodulatory agents, as suggested by prior work with other drugs in this class. [50] [51] [52] Correlative studies, particularly that link genetic polymorphisms at FcgRIIIA-158 with outcome, should provide insight into the importance of NK cells in clinical response.
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